Lung Diffusing Capacity Improves the Prognostic Validity of the GOLD Spirometric Staging in COPD.

Area of Science:

• Pulmonary Medicine
• Respiratory Physiology

Background:

• Lung diffusing capacity for carbon monoxide (DLco) measures gas transfer and offers distinct physiological insights compared to spirometry.
• DLco independently predicts mortality in COPD, but its role alongside GOLD spirometric staging for risk assessment is not well-established.

Purpose of the Study:

• To evaluate if incorporating DLco measurements into the GOLD spirometric classification improves the prediction of all-cause and respiratory mortality in COPD patients.

Main Methods:

• A prospective cohort study followed 469 COPD patients for up to 10 years, assessing mortality outcomes.
• Patients were categorized by DLco impairment (<50% predicted). Cox proportional hazard models analyzed the added prognostic value of DLco to GOLD FEV1 staging.
• Findings were validated in a separate Canadian COPD cohort (N=300).

Main Results:

• DLco <50% independently predicted higher all-cause (HR=1.83) and respiratory mortality (HR=2.27).
• Integrating DLco into GOLD staging significantly increased mortality risk prediction, particularly for GOLD stages 3 and 4.
• Survival time decreased by over a year for all-cause and respiratory deaths in higher GOLD stages when DLco was considered.

Conclusions:

• Combining DLco with FEV1 enhances the prognostic accuracy of the GOLD classification for COPD.
• This integrated approach is particularly beneficial for identifying high-risk patients in GOLD stages 3-4, improving adverse outcome prediction.